World News: 08:36 GMT Thursday 6th December 2018. [Oncology Venture A/S via Globe Newswire via SPi World News]
The current OV product portfolio includes LiPlaCis a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast and prostate cancer 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast cancer; dovitinib a post phase 3 product which w...
Globe Newswire: 08:36 GMT Thursday 6th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.